International external quality assurance of JAK2 V617F quantification.


Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
May 2019
Historique:
received: 11 11 2018
accepted: 26 11 2018
pubmed: 12 12 2018
medline: 26 4 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is important that EQA for quantitative analysis takes into account the variation in methodology. Results cannot be expected to be more accurate than limits of the technology used, and it is essential to recognize factors causing substantial outlier results. The present study aimed to identify parameters of specific importance for JAK2 V617F quantification by quantitative PCR, using different starting materials, assays, and technical platforms. Sixteen samples were issued to participating laboratories in two EQA rounds. In the first round, 19 laboratories from 11 European countries analyzing JAK2 V617F as part of their routine diagnostics returned results from in-house assays. In the second round, 25 laboratories from 17 countries participated. Despite variations in starting material, assay set-up and instrumentation the laboratories were generally well aligned in the EQA program. However, EQA based on a single technology appears to be a valuable tool to achieve standardization of the quantification of JAK2 V617F allelic burden.

Identifiants

pubmed: 30535576
doi: 10.1007/s00277-018-3570-8
pii: 10.1007/s00277-018-3570-8
pmc: PMC6469832
doi:

Substances chimiques

JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1111-1118

Subventions

Organisme : Austrian Science Fund
ID : F4702-B20 and P29018-B30

Références

N Engl J Med. 2003 Oct 9;349(15):1423-32
pubmed: 14534335
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187
Clin Chem Lab Med. 2005;43(5):542-8
pubmed: 15899677
Blood. 2006 May 1;107(9):3676-82
pubmed: 16373657
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Blood. 2006 Sep 15;108(6):1865-7
pubmed: 16728702
Leukemia. 2007 May;21(5):1128-30
pubmed: 17301814
Br J Haematol. 2007 Mar;136(5):745-51
pubmed: 17313377
Blood. 2008 Oct 15;112(8):3065-72
pubmed: 18650451
Haematologica. 2009 Jan;94(1):38-45
pubmed: 19001280
Blood. 2010 Nov 25;116(22):e111-7
pubmed: 20720184
Br J Haematol. 2013 Jan;160(1):25-34
pubmed: 23057517
Leukemia. 2013 Oct;27(10):2032-9
pubmed: 23860450
Leukemia. 2015 Feb;29(2):369-76
pubmed: 25036192
Leuk Lymphoma. 2016 Feb;57(2):348-354
pubmed: 25956046
Oncotarget. 2017 May 16;8(20):32608-32617
pubmed: 28427233

Auteurs

Julia Asp (J)

Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. julia.asp@gu.se.

Vibe Skov (V)

Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Beatriz Bellosillo (B)

Department of Pathology, Hospital del Mar, Barcelona, Spain.

Thomas Kristensen (T)

Department of Pathology, Odense University Hospital, Odense, Denmark.

Eric Lippert (E)

CHU de Brest, Brest, France.

Frank Dicker (F)

Munich Leukemia Laboratory, Munich, Germany.

Jiri Schwarz (J)

Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

Marzena Wojtaszewska (M)

Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

Lars Palmqvist (L)

Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Susanna Akiki (S)

Department of Laboratory Medicine and Pathology, Qatar Rehabilitation Institute (QRI), Hamad Bin Khalifa Medical City (HBKM), Doha, Qatar.

Anni Aggerholm (A)

Aarhus University Hospital, Aarhus, Denmark.

Morten Tolstrup Andersen (M)

Rigshospitalet, Copenhagen, Denmark.

François Girodon (F)

CHU Dijon/INSERM U866, Dijon, France.

Lasse Kjær (L)

Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Elisabeth Oppliger Leibundgut (E)

University Hospital Bern and University of Bern, Bern, Switzerland.

Alessandro Pancrazzi (A)

Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Florence, Italy.

Marta Vorland (M)

Haukeland University Hospital, Bergen, Norway.

Hajnalka Andrikovics (H)

Central Hospital of Southern Pest, Budapest, Hungary.

Robert Kralovics (R)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, and Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Bruno Cassinat (B)

Service de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France.

Margarida Coucelo (M)

Clinical Hematology Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

Aleksandar Eftimov (A)

Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, UKiM, Skopje, Republic of Macedonia.

Karl Haslam (K)

St James's Hospital, Dublin, Ireland.

Rajko Kusec (R)

Dubrava University Hospital and Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia.

Dorota Link-Lenczowska (D)

Molecular Diagnostics Laboratory, Hematology Diagnostics Department, Jagiellonian University Hospital, Krakow, Poland.

Laurence Lodé (L)

Hématologie Biologique, CHRU de Montpellier, Montpellier, France.

Karolina Matiakowska (K)

Faculty of Medicine, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Dina Naguib (D)

CHU Côte de Nacre, Caen, France.

Filippo Navaglia (F)

Department of Laboratory Medicine, University - Hospital of Padova, Padova, Italy.

Guy Wayne Novotny (GW)

Department of Hematology and Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730, Herlev, Denmark.

Melanie J Percy (MJ)

Belfast City Hospital, Belfast, UK.

Andrey Sudarikov (A)

National Research Center for Hematology, Moscow, Russia.

Sylvie Hermouet (S)

Laboratory of Hematology, University Hospital (CHU) Nantes, Nantes, France.
CRCINA, Inserm UMR892 / CNRS UMR6299, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université de Nantes, Nantes, France.

Niels Pallisgaard (N)

Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH